4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      What one pandemic can teach us in facing another

      research-article
      AIDS (London, England)
      Lippincott Williams & Wilkins
      COVID-19 pandemic, HIV pandemic, lessons learned

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Almost exactly 39 years ago, the US Centers for Disease Control reported five cases of Pneumocystis carinii pneumonia among previously healthy gay men [1]. By the end of 1985, HIV was reported from every region in the world. Three decades later, 75 million people have acquired HIV and about 32 million have died from it [2]. HIV was the first pandemic that shaped my career – as it has for so many of my peers. Indeed, it fundamentally changed how we think about and respond to major health threats. HIV continues to be a clarion call – for countless scientists, health providers and community advocates around the world. And, sadly, four decades on, this pandemic still rages across the globe. Today, for the first time in history, the world is experiencing two pandemics at the same time. What are the similarities and differences between the two pandemics? Are there lessons learned from confronting HIV that should guide the response to COVID-19 pandemic? In terms of similarities, both pandemics are caused by zoonotic viruses. For HIV, research confirmed that the virus was transmitted from nonhuman primates to humans while SARS-CoV-2 is thought to have originated in bats [3,4]. In addition, both viruses are transmitted from person to person. The predominance of HIV transmission through sexual route and via injection drug use has resulted in profound stigma associated with it [5–7]. At the same time, COVID-19-related stigma has already been noted, including blaming outsiders [8]. Another similarity is that both epidemics have shed light on gaps in health systems. HIV, as a chronic communicable disease, required a transformation from a focus on acute care to be able to deliver on the chronic and ongoing needs of people living with HIV [9,10]. The COVID-19 pandemic, in contrast, has highlighted the fragility of surveillance and contact tracing systems, the paucity of measures to protect health providers, and the limited infrastructure for advanced care [11–14]. The good news is that the decades of struggles in confronting the HIV epidemic provide important lessons relevant to the control of the COVID-19 pandemic. Firstly, political leadership is critically important. The early denial of the HIV epidemic in South Africa and the United States resulted in unnecessary loss of life [15–17]. Early denial of the risk of COVID-19 by leadership in the United States resulted in it leading the world in the number of cases and deaths. Similar reluctance in Brazil has resulted in the country leading all Latin American countries in the number of COVID-19 cases with an alarming number of deaths [18,19]. Secondly, perhaps the most durable legacy of the HIV response is the recognition of the critical importance of engaging communities, whether through the early voices of gay advocates in the United States or the vibrant participation of people living with HIV as peer educators around the world [20,21]. It has rapidly become evident that COVID-19 is disproportionately affecting African Americans and Latinos in the United States, with data showing them to be twice as likely to die from COVID-19. Similar adverse impacts have been noted among vulnerable populations in country after country around the world. We need to take the lessons learned from HIV and work to engage the communities most severely impacted by COVID-19. Thirdly, it is widely acknowledged that the successful global response to the HIV epidemic was because of strengthening all pillars of the health system [22]. Addressing the need for lifelong treatment for HIV required investment in laboratory and medication procurement systems, training and mentorship of diverse health cadres and development of innovative models of care. A similar comprehensive approach is needed in order to ensure an effective response to COVID-19. Fourthly, while during the early desperate years of the HIV epidemic, advocates reached for unproven treatment, they quickly became strong supporters of science-based interventions [23–25]. The harm caused by unproven HIV treatments should inspire caution and motivate a commitment to rigorous science in evaluating potential treatments and preventive measures for COVID-19. Fifthly, the HIV epidemic showed us the importance of using data to inform action. National surveys in African countries provide this kind of granular data [26]. COVID-19 data from New York City, as another example, point to specific zip codes with the highest burden of COVID-19 [27]. These are the areas where we must focus our efforts in order to achieve equity, where intensive outreach is needed, and where testing sites and treatment resources should be situated to allow for rapid identification of cases. Lastly, epidemics thrive on mistrust and myths. Conspiracy theories about HIV has jeopardized lives by provoking reluctance to get tested or to initiate treatment. As we face the COVID-19 epidemic, it behoves us to take the lessons from HIV to heart and identify trusted spokespersons armed with accurate information who can reach the affected populations with reliable information. Experiencing two concomitant pandemics is unprecedented. Although attention has shifted to COVID-19, I fear we risk forgetting that the HIV pandemic still affects millions of people. We risk turning our attention to the issue of the moment, neglecting other health threats that people face. With a generation of experience as our guide, I am hopeful that the lessons learned from the first pandemic that defined my career can help bring the second one under control and with far fewer lives lost. Acknowledgements The author gratefully acknowledge inputs from Jessica Justman and Joey Platt. Conflicts of interest There are no conflicts of interest.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: found

          Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

            Summary As coronavirus disease 2019 (COVID-19) spreads across the world, the intensive care unit (ICU) community must prepare for the challenges associated with this pandemic. Streamlining of workflows for rapid diagnosis and isolation, clinical management, and infection prevention will matter not only to patients with COVID-19, but also to health-care workers and other patients who are at risk from nosocomial transmission. Management of acute respiratory failure and haemodynamics is key. ICU practitioners, hospital administrators, governments, and policy makers must prepare for a substantial increase in critical care bed capacity, with a focus not just on infrastructure and supplies, but also on staff management. Critical care triage to allow the rationing of scarce ICU resources might be needed. Researchers must address unanswered questions, including the role of repurposed and experimental therapies. Collaboration at the local, regional, national, and international level offers the best chance of survival for the critically ill.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Zoonotic origins of human coronaviruses

              Mutation and adaptation have driven the co-evolution of coronaviruses (CoVs) and their hosts, including human beings, for thousands of years. Before 2003, two human CoVs (HCoVs) were known to cause mild illness, such as common cold. The outbreaks of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) have flipped the coin to reveal how devastating and life-threatening an HCoV infection could be. The emergence of SARS-CoV-2 in central China at the end of 2019 has thrusted CoVs into the spotlight again and surprised us with its high transmissibility but reduced pathogenicity compared to its sister SARS-CoV. HCoV infection is a zoonosis and understanding the zoonotic origins of HCoVs would serve us well. Most HCoVs originated from bats where they are non-pathogenic. The intermediate reservoir hosts of some HCoVs are also known. Identifying the animal hosts has direct implications in the prevention of human diseases. Investigating CoV-host interactions in animals might also derive important insight on CoV pathogenesis in humans. In this review, we present an overview of the existing knowledge about the seven HCoVs, with a focus on the history of their discovery as well as their zoonotic origins and interspecies transmission. Importantly, we compare and contrast the different HCoVs from a perspective of virus evolution and genome recombination. The current CoV disease 2019 (COVID-19) epidemic is discussed in this context. In addition, the requirements for successful host switches and the implications of virus evolution on disease severity are also highlighted.
                Bookmark

                Author and article information

                Journal
                AIDS
                AIDS
                AIDS
                AIDS (London, England)
                Lippincott Williams & Wilkins (Hagerstown, MD )
                0269-9370
                1473-5571
                1 October 2020
                03 September 2020
                : 34
                : 12
                : 1757-1759
                Affiliations
                ICAP at Columbia University, Mailman School of Public Health, New York, New York, USA.
                Author notes
                Correspondence to Wafaa M. El-Sadr, MD, MPH, MPA, ICAP at Columbia University, Mailman School of Public Health, 722 West 168th Street, Room 1312, New York, NY 10032, USA. Tel: +1 212 342 0532; e-mail: wme1@ 123456columbia.edu
                Article
                AIDS-D-20-00539
                10.1097/QAD.0000000000002636
                7493777
                32675579
                79101c74-7c26-457f-bf49-4fe3a6b9ca4c
                Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

                This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                : 15 June 2020
                : 03 July 2020
                Categories
                Clinical Science: Special Section: Covid-19 among People Living with HIV
                Custom metadata
                TRUE

                covid-19 pandemic,hiv pandemic, lessons learned
                covid-19 pandemic, hiv pandemic, lessons learned

                Comments

                Comment on this article